×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
JAZZ – jazz pharmaceuticals plc - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
JAZZ
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/19
02:24 pm
jazz
Jazz Pharmaceuticals (JAZZ) had its price target raised by Piper Sandler from $219.00 to $232.00. They now have an "overweight" rating on the stock.
Low
Report
Jazz Pharmaceuticals (JAZZ) had its price target raised by Piper Sandler from $219.00 to $232.00. They now have an "overweight" rating on the stock.
3/19
08:01 am
jazz
Jazz Pharmaceuticals to present clinical, preclinical data at AACR 2026 [Yahoo! Finance]
Medium
Report
Jazz Pharmaceuticals to present clinical, preclinical data at AACR 2026 [Yahoo! Finance]
3/19
06:35 am
jazz
A Look At Jazz Pharmaceuticals (JAZZ) Valuation As New Oncology Data Heads To The 2026 AACR Meeting [Yahoo! Finance]
Low
Report
A Look At Jazz Pharmaceuticals (JAZZ) Valuation As New Oncology Data Heads To The 2026 AACR Meeting [Yahoo! Finance]
3/18
07:54 am
jazz
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026 [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026 [Yahoo! Finance]
3/18
07:44 am
jazz
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
Low
Report
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
3/12
12:16 pm
jazz
Jazz Pharmaceuticals plc (JAZZ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Jazz Pharmaceuticals plc (JAZZ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/9
05:01 pm
jazz
Jazz Pharmaceuticals (JAZZ) had its "overweight" rating reaffirmed by Barclays PLC.
Low
Report
Jazz Pharmaceuticals (JAZZ) had its "overweight" rating reaffirmed by Barclays PLC.
3/9
07:35 am
jazz
S&P 500 Futures Fall in Premarket Trading; Jazz Pharmaceuticals, Live Nation Ent Lead [Barron's]
Low
Report
S&P 500 Futures Fall in Premarket Trading; Jazz Pharmaceuticals, Live Nation Ent Lead [Barron's]
Date
Time
Symbol
Company Name
Action
%Chg
2/24/2026
04:05 pm
jazz
jazz pharmaceuticals plc - ordinary shares
BEAT
Report
13.2%
jazz pharmaceuticals plc - ordinary shares
11/5/2025
04:05 pm
jazz
jazz pharmaceuticals plc - ordinary shares
BEAT
Report
-2.3%
jazz pharmaceuticals plc - ordinary shares
8/5/2025
04:05 pm
jazz
jazz pharmaceuticals plc - ordinary shares
MISS
Report
-6.4%
jazz pharmaceuticals plc - ordinary shares
5/6/2025
04:08 pm
jazz
jazz pharmaceuticals plc - ordinary shares
MISS
Report
-3.4%
jazz pharmaceuticals plc - ordinary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/9
05:31 pm
jazz
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: COZADD BRUCE C
Low
Report
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: COZADD BRUCE C
3/9
05:27 pm
jazz
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: Johnson Philip L
Low
Report
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: Johnson Philip L
3/9
05:25 pm
jazz
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: Henderson Mary Elizabeth
Low
Report
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: Henderson Mary Elizabeth
3/9
05:23 pm
jazz
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: Pearce Samantha
Low
Report
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: Pearce Samantha
3/9
05:21 pm
jazz
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: Iannone Robert
Low
Report
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: Iannone Robert
3/9
05:16 pm
jazz
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: Carr Patricia
Low
Report
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: Carr Patricia
3/9
05:10 pm
jazz
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: GALA RENEE D
Low
Report
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: GALA RENEE D
3/9
05:07 pm
jazz
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: Patil Neena M
Low
Report
Form 4 Jazz Pharmaceuticals For: Mar 05 Filed by: Patil Neena M
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/7
Q1/2019 3/31/2019 EPS 3.670 ZacksConsensus 2.830 ActVsEst 0.840 - Beat
9.3%
4/6 Jefferies sees 51% upside in Jazz Pharma in premarket analyst action [Seeking Alpha] 7.1%
9/10 Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. 5.0%
11/14 Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences 3.7%
11/7 Form 3 Jazz Pharmaceuticals For: Oct 31 Filed by: Larkin Finbar 3.3%
1/14 Form 8-K Jazz Pharmaceuticals For: Jan 13 3.0%
4/24 Form 10-K/A Jazz Pharmaceuticals For: Dec 31 2.8%
12/19 PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S. 2.6%
11/22 Edited Transcript of JAZZ earnings conference call or presentation 5-Nov-19 9:30pm GMT [Yahoo! Finance News] 2.6%
4/28 Can This Small-Cap Biotech Win a $1 Billion Market Opportunity for Narcolepsy? [The Motley Fool] 2.5%
4/6 Jefferies sees 51% upside in Jazz Pharma in premarket analyst action [Seeking Alpha] 7.1%
9/10 Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. 5.0%
11/14 Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences 3.7%
11/7 Form 3 Jazz Pharmaceuticals For: Oct 31 Filed by: Larkin Finbar 3.3%
1/14 Form 8-K Jazz Pharmaceuticals For: Jan 13 3.0%
4/24 Form 10-K/A Jazz Pharmaceuticals For: Dec 31 2.8%
12/19 PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S. 2.6%
11/22 Edited Transcript of JAZZ earnings conference call or presentation 5-Nov-19 9:30pm GMT [Yahoo! Finance News] 2.6%
4/28 Can This Small-Cap Biotech Win a $1 Billion Market Opportunity for Narcolepsy? [The Motley Fool] 2.5%
TOP News Decliners
3/13
Form 4 Jazz Pharmaceuticals For: Mar 12 Filed by: MILLER MICHAEL PATRICK
-11.3%
2/25 Q4/2019 12/31/2019 EPS 4.420 ZacksConsensus 3.610 ActVsEst 0.810 - Beat -8.4%
3/3 Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -7.8%
6/17 Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi™ (solriamfetol) -7.1%
10/7 Form 8-K Jazz Pharmaceuticals For: Oct 03 -5.6%
8/6 Jazz Pharmaceuticals Announces Second Quarter 2019 Financial Results -4.8%
11/5 Jazz Pharmaceuticals EPS beats by $0.51, beats on revenue [Seeking Alpha] -4.3%
3/31 Jazz Pharmaceuticals Provides COVID-19 Business Update -4.1%
3/5 Form 4 Jazz Pharmaceuticals For: Mar 03 Filed by: Carr Patricia -3.8%
4/29 Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease -3.6%
2/25 Q4/2019 12/31/2019 EPS 4.420 ZacksConsensus 3.610 ActVsEst 0.810 - Beat -8.4%
3/3 Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -7.8%
6/17 Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi™ (solriamfetol) -7.1%
10/7 Form 8-K Jazz Pharmaceuticals For: Oct 03 -5.6%
8/6 Jazz Pharmaceuticals Announces Second Quarter 2019 Financial Results -4.8%
11/5 Jazz Pharmaceuticals EPS beats by $0.51, beats on revenue [Seeking Alpha] -4.3%
3/31 Jazz Pharmaceuticals Provides COVID-19 Business Update -4.1%
3/5 Form 4 Jazz Pharmaceuticals For: Mar 03 Filed by: Carr Patricia -3.8%
4/29 Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease -3.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: